Retatrutide Heart Health: What's Proven and What's Not

Retatrutide heart health, in one line: better heart numbers, unproven heart protection. In TRIUMPH-1, the top dose lowered systolic blood pressure about 10 points (vs. about 2 on placebo) and triglycerides about 38% at 80 weeks. But no trial has shown it prevents heart attacks or strokes, average pulse rose, and it isn't FDA-approved.

That answer matters more for some people than others. If you already have heart disease, take blood pressure pills, or bought something sold online as retatrutide, a few details below are written for you. The scorecard right under this puts 6 trials side by side, including the heart-event result that needs context: 27 heart attacks, strokes, or heart deaths on retatrutide vs. 23 on placebo. That difference was inconclusive. And if you want heart protection you can actually get today, we'll show you which GLP-1 has it on its FDA label.

If your heart rate is suddenly very high or very low for you, especially with chest pain, shortness of breath, dizziness, or fainting, call 911. (American Heart Association)

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The Retatrutide Heart Health Scorecard: 6 Trials Side by Side

Taken together, these six trials report improvements in blood pressure, triglycerides, cholesterol, and a marker of inflammation. TRIUMPH-3, which specifically studied people with heart disease, found no clear difference from placebo in heart attacks, strokes, or heart deaths. Resting pulse rose slightly on average.

How to read this table:

• TRIUMPH-1 rows come from the New England Journal of Medicine paper and appendix (Sept. 29, 2026 version). The blood-pressure, blood-fat, inflammation, and waist figures compare the top study dose (12 mg) with placebo at 80 weeks. They are each group's estimated change from where it started—not the difference between groups. The treatment-regimen analysis includes people regardless of whether they stopped treatment. Pulse comes from a separate safety analysis. The side-effect percentages count people who received at least one dose: 582 on 12 mg and 586 on placebo. The heart-event row covers all three retatrutide doses.
• Lilly's news releases often show bigger "up to" numbers. Their efficacy analysis estimates what would happen if everyone stayed on the assigned treatment without starting a prohibited weight-management treatment. It is not simply a count of people who finished. In the tables below, "points" means mmHg, the unit used for blood pressure.
• TRIUMPH-3 rows combine the 9 mg and 12 mg groups. The counts are people with a first qualifying event during the study. They come from Lilly's July 23, 2026 announcement; we found no full journal report of these results as of October 24, 2026.
• Doses here only name study groups. They aren't treatment instructions.

The 6 trials behind the scorecard

Here's the trap this table helps you avoid. Say a friend reads "retatrutide lowers blood pressure 10 points" and decides it protects the heart. The headline is true. But blood pressure is a reading on a gauge. Whether fewer people actually had heart attacks is a different row, and that row still says "not proven."

RX Index Decision Verdict: Retatrutide for heart health — promising numbers, unproven protection, not FDA-approved. Best for: People following the research, or who may qualify for a clinical trial. Not ideal for: Anyone who needs heart protection now. If you meet its label's criteria, an FDA-approved GLP-1 with heart evidence is an option to ask your doctor about. The factor that matters most: Proof of fewer heart attacks and strokes on the FDA label, not just better lab numbers.

One honest limit: no trial average can tell you whether retatrutide would be safe for your heart. And it isn't available as a routine approved prescription today. But if heart protection is what you're after, you don't have to wait for it.

Some FDA-approved GLP-1s already have heart protection on their label. Which path fits depends on your health, state, insurance and drug list, budget, and whether you want a pill or shot. The RX Index's Find My GLP-1 Path tool asks a few quick questions and suggests a provider path and pricing to review based on your goals, budget, insurance, and preferences. It's free, takes about 2 minutes, and needs no signup. It can't tell you what's safe for your heart or confirm your plan's coverage. That part belongs to your doctor and your insurer.

See which GLP-1 path fits you

Did Retatrutide Lower Heart Attacks and Strokes? What TRIUMPH-3 Found

Retatrutide has not proved it lowers heart attacks or strokes. In TRIUMPH-3, 1,949 people with severe obesity and heart disease were followed for 80 weeks: 27 on retatrutide and 23 on placebo had a heart attack, stroke, or heart-related death. Lilly reported these results in July 2026; we found no full journal report as of October 24, 2026. (Lilly announcement)

What TRIUMPH-3 was built to test

TRIUMPH-3's main job was measuring weight loss in people who already have heart disease. The 12 mg group lost an estimated average of 22.6% of body weight in the analysis that assumes continued treatment. Heart events were counted as extra, planned-ahead analyses.

People were split 1:1:2 into 9 mg, 12 mg, or placebo. So the two retatrutide groups together were about the same size as the placebo group. The formal analysis also accounts for how long people were followed; the counts alone don't give the full answer.

What the numbers mean

Source: Lilly, July 23, 2026, pre-planned analyses counting all study time. Company-reported.

A hazard ratio compares how often events happened over time. A ratio of 1.0 means no difference. Below 1 leans toward fewer events on retatrutide, and above 1 leans toward more.

The ranges show the uncertainty around each estimate. Both include 1.0, so neither analysis establishes a benefit or an increase in harm.

In plain terms: for the narrow count, the range runs from an event rate about a third lower to nearly double. For the broader count, it runs from 45% lower to 22% higher. That's too wide to call either way.

Why do the two counts lean different ways? The broader one adds deaths from any cause, heart-failure events, and stents or bypass surgery. With this few events, a handful either way moves the numbers a lot. Lilly said heart events happened "less frequently than anticipated" in both groups. Fewer events means a fuzzier answer.

Lilly also ran a second look that excluded events more than 35 days after people stopped their study treatment (hazard ratio 0.73 for MACE-5 and 0.92 for MACE-3). That one wasn't planned ahead of time, so the results above carry more weight. For more on how these event counts work, see what MACE means in GLP-1 heart trials.

TRIUMPH-3 vs. TRIUMPH-Outcomes: the trial designed to answer it

TRIUMPH-Outcomes is the trial designed to answer the heart question. Lilly lists it as a study of about 10,000 adults age 45 and older with a BMI of 27 or more and artery disease, kidney disease, or both. It runs from April 2024 to an estimated February 2029.

February 2029 is the study's estimate, not an approval date or a promised results date. For every retatrutide study and its status, see our retatrutide clinical trials tracker or the official trial record.

Does Retatrutide Lower Blood Pressure?

Retatrutide lowered blood pressure in the trials summarized here. In TRIUMPH-1, the top dose lowered the top (systolic) number by 10.4 points over 80 weeks, compared with 1.9 points on placebo. For some people already taking blood pressure pills, it dropped too far.

The company numbers come from Lilly's releases linked in the trials table above. Placebo groups changed too. The journal paper shows that, while the releases mostly show the retatrutide side. These are changes within each group, not placebo-adjusted differences, and the trials studied different people. The table does not rank which trial showed the best effect.

Can blood pressure drop too low on retatrutide?

Sometimes. In TRIUMPH-1, 51 people on the top dose (8.8%) had a low-blood-pressure side effect, compared with 5 people (0.9%) on placebo. These events were more common in people taking blood pressure medicine.

That count includes low blood pressure, blood pressure dropping when standing up, and blood pressure decreases reported as side effects. The paper says most were mild or moderate. Dizziness showed up in 12.0% on the top dose vs. 3.1% on placebo. In the earlier Phase 2 trial, blood pressure fell enough that study doctors stopped at least one blood pressure medicine for some participants.

Here's what that looks like in real life. Say you're 58 and take two blood pressure pills. As weight comes off, the dose that was just right can become too much. That's why a home blood pressure cuff and a plan with your doctor matter more than any trial average. Never stop or change a blood pressure medicine on your own. For warning signs and what reading is too low, see how GLP-1 treatments affect blood pressure.

How can blood pressure go down while pulse goes up?

They measure different things. Blood pressure is the force of blood pushing through your vessels. Pulse is how many times your heart beats per minute. (American Heart Association)

So one can fall while the other rises. Think of a garden hose: pressure is how hard the water pushes, and pulse is how often the pump kicks. Trials can't tell you why your pulse changed. Your doctor can help sort that out.

Does Retatrutide Lower Cholesterol and Triglycerides?

Retatrutide lowered blood fats in TRIUMPH-1, especially triglycerides. In that trial, triglycerides fell 38.0% on the top dose vs. 3.0% on placebo, and non-HDL cholesterol fell 20.6% vs. 4.6%. Better lab numbers are good signs, but they aren't the same as fewer heart attacks.

Triglycerides are a type of fat in your blood. Non-HDL cholesterol is your total cholesterol minus the "good" HDL kind, so it bundles all the kinds linked to clogged arteries. LDL ("bad") cholesterol dropped less, 16.3% vs. 4.7%. HDL ("good") cholesterol rose 9.4% vs. 1.3%. hsCRP, a blood test for inflammation, fell 62.6% vs. 24.9%.

The later trials told the same triglyceride story. TRIUMPH-2 showed drops up to 39.5%, and TRIUMPH-3 up to 37.0% (company numbers).

Can retatrutide replace a statin? It has not been shown to do that. Statins have their own track record on heart attacks and strokes, so don't stop one without your doctor. More on this in how GLP-1s affect cholesterol.

Does Retatrutide Raise Heart Rate or Cause Rhythm Problems?

Retatrutide raises resting pulse a little on average. In TRIUMPH-1, pulse peaked around week 20 and, at 80 weeks, sat 2.6 beats per minute above where it started on the top dose (vs. 0.3 below on placebo). Severe or serious rhythm or heart-conduction problems were reported in 5 people on the top dose and 5 on placebo—0.9% in each group. Those small counts do not prove the risks are equal. (TRIUMPH-1, Table 3 and appendix)

The 2023 Phase 2 trial saw the same pattern: pulse rose with the dose, peaked at 24 weeks, then eased. Reported rhythm problems were mild to moderate, with one exception. One participant who was also given ondansetron, an anti-nausea drug, had a severe prolonged QT event. The QT interval is the heart's electrical reset between beats. The report doesn't show which drug caused it.

Here's a useful comparison. Wegovy also raised pulse in its big heart trial, by 3.8 beats per minute vs. 0.7 on placebo at two years. Even so, the combined rate of heart attacks, strokes, or heart deaths went down. (Wegovy label) So a small pulse rise doesn't decide the outcome by itself. Doctors still take a lasting rise seriously, though: Wegovy's label tells clinicians to stop treatment if resting heart rate stays up. That is a reason to contact your prescriber, not to change treatment on your own.

An average isn't you. If you notice a new or lasting racing, pounding, or skipping heartbeat, talk to your doctor, or your study team if you're in a trial. For the dose-by-dose numbers and warning signs, see retatrutide heart rate: how much it rises and when to worry.

Is Retatrutide Safe if You Already Have Heart Disease?

Retatrutide's long-term safety for people with heart disease is not established. TRIUMPH-3 included people with heart disease and didn't show a clear rise or drop in heart events, but its main goal was weight loss. Retatrutide isn't FDA-approved, so there's no FDA-approved prescribing label for heart patients.

Who the trials left out

The TRIUMPH-1 appendix says the trial didn't enroll anyone who'd had one of these in the past 90 days:

• A heart attack or stroke
• A procedure to open a heart artery
• A hospital stay for unstable angina or heart failure

It also left out anyone with the most severe level of heart failure (NYHA class IV). If one of those describes you, the trial numbers tell you even less about your situation.

What happened to people in TRIUMPH-1

Heart events were rare: 9 people across the three retatrutide doses (0.2% to 0.9% per group) vs. 1 person on placebo (0.2%). That's too few to establish heart protection or safety. The paper itself says the trial "was not powered to assess cardiovascular safety." The three retatrutide groups together had about three times as many people as the placebo group.

Deaths were also rare: 4 across the retatrutide groups and 2 on placebo. Of the 4 on retatrutide, one was judged heart-related, in a person with known heart failure about six months after stopping the drug. One cause couldn't be determined, and two weren't heart-related.

Heart failure is still an open question

Retatrutide has not been shown to prevent heart-failure events. TRIUMPH-3 included them in its broader event count, but that result was inconclusive. TRIUMPH-Outcomes counts heart-failure hospital stays and urgent visits as part of its main heart result, so it is designed to give a clearer answer.

Which GLP-1 Is Proven to Protect Your Heart Today?

For adults without diabetes, Wegovy is the weight-loss GLP-1 with heart protection on its FDA label. In its heart trial of 17,604 adults with heart disease and overweight or obesity, the combined heart-attack, stroke, or heart-death result happened in 6.5% on Wegovy vs. 8.0% on placebo, a 20% lower relative risk over the study. That is 1.5 fewer people per 100, not 20 fewer per 100. For people with type 2 diabetes and heart disease, Ozempic also has a heart-protection label.

Sources: Wegovy label (revised June 2026), Ozempic label (revised May 2026), Zepbound label (revised August 2026), SUMMIT trial, and SURMOUNT-MMO listing, checked October 24, 2026.

Tirzepatide, the medicine in Zepbound, reduced the combined risk of worsening heart failure or heart-related death in SUMMIT. That trial studied people with obesity and heart failure with preserved ejection fraction—a type of heart failure in which the heart still pumps out a normal share of blood with each beat. It does not give Zepbound an FDA-approved heart indication or prove fewer heart attacks and strokes in everyone with obesity.

Two cautions keep this table honest:

• These aren't head-to-head results. Different trials studied different people, so the percentages can't be compared one to one.
• Wegovy's label covers both the shot and the pill, but the heart trial tested the shot.

Do you count as having "heart disease"?

Wegovy's heart trial defined it as having had a heart attack, a stroke, or symptomatic peripheral artery disease (narrowed arteries that cause symptoms, often in the legs). High blood pressure or high cholesterol alone wasn't on that list. Insurers can add their own rules. See what insurers mean by heart disease for Wegovy.

What about compounded GLP-1s? Compounded semaglutide and tirzepatide aren't FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients, and the brand-name heart trials do not establish heart protection for compounded versions. Retatrutide cannot legally be used in compounding. (FDA) For the bigger picture, see the best GLP-1 for heart protection and Wegovy for heart disease.

What Should You Do Now? Pick Your Situation

Your next step depends on three things: whether you have heart disease, what insurance you have, and whether you're already using something sold as retatrutide. Find the row that fits you.

If you're in the first row, start with your doctor and insurer. Wegovy for heart disease often needs prior authorization, which is a permission slip from your insurer. Your prescriber submits the medical records your plan asks for.

Ro is one example of a provider that offers insurance help. It advertises a free coverage check for select pens, including Wegovy. If a Ro clinician prescribes treatment, its insurance team can submit the prior authorization. That does not guarantee approval. (Ro insurance)

Here's what Ro publishes for fees and medication prices, checked October 24, 2026 (Ro pricing):

• Ro membership: $39 for the first month, refunded if you're not eligible for GLP-1s. After that, the monthly plan is $149. The annual plan is $888 paid up front, equal to $74 a month. Medication costs extra.
• Wegovy pill, cash: $149 for the starter 1.5 mg strength, $199 for 4 mg, and $299 for 9 mg or 25 mg. Each fill is 30 tablets, a 30-day supply. The label's maintenance strength is 25 mg, so $149 is not the ongoing maintenance price.
• Wegovy pen, cash: $349 per 28-day fill for 0.25–2.4 mg, or $399 for 7.2 mg. The 7.2 mg strength is labeled for weight management, not heart-risk maintenance. Eligible new patients can get their first two 28-day fills of 0.25 or 0.5 mg for $199 each. The offer must be redeemed and each prescription filled by Dec. 31, 2026; signing up alone does not qualify. "New" means no Wegovy injection savings offer used in the past 365 days. (Manufacturer terms)
• Maintenance-pill example: a $299 fill plus membership works out to about $373–$448 a month for budgeting. The lower figure spreads the $888 annual membership payment over 12 months. Optional multi-month medication discounts and extra services are not included in this example.

Membership includes care, support, and necessary program lab tests. Ro says cash-pay Wegovy ships free. Its terms list 24 medical consultations per year, with $15 for each extra consultation and separate fees for extra lab tests. Membership renews automatically. Paid membership fees are nonrefundable under the terms, with exceptions such as rejected or expired treatment requests. Cancel at least 48 hours before renewal to avoid the next membership charge. We did not complete checkout or test the insurance checker.

On Medicare or Medicaid? Start with your plan instead. Ro says people with Medicaid are not eligible for treatment through its program. (Ro insurance)

Bought "Research" Retatrutide Online? What It Means for Your Heart

A vial sold online as a "research peptide" is not proof that you have the product used in these trials. The FDA says retatrutide isn't approved and can't be used in compounding under federal law. It warns that products falsely sold for research or "not for human consumption" are of unknown quality and may be harmful. The heart results above do not establish what is in your vial or how it will affect you.

The FDA has warned telehealth companies, ingredient suppliers, and large compounding facilities about retatrutide. It has also targeted "research use" sellers.

There's also an early warning sign from real-world reports. A JAMA Network Open study (Oct. 14, 2026) identified 13,589 Reddit accounts reporting retatrutide use. Heart-rate and pulse terms were more prominent than in earlier semaglutide or tirzepatide discussions, but the groups were not matched and no statistical comparison was made. The researchers could not verify the products or users' medical histories. These reports cannot show how often side effects happen or which drug is safer, but they are a reason to study the safety concerns.

If this is you:

1. Tell your doctor exactly what you're using, and bring the vial or label.
2. Don't change heart or blood pressure medicines on your own.
3. Use the 911 signs at the top of this page.

To see why a pharmacy can't legally make it, read compounded retatrutide: is it legal?. For red flags on any online seller, see how to spot fake GLP-1 medications.

When Will We Know if Retatrutide Protects the Heart?

The main heart-and-kidney trial, TRIUMPH-Outcomes, has an estimated end date of February 2029—not a promised results date. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027, based on its obesity trial program. Submission and approval are separate steps.

• Now: Heart-risk numbers improved; TRIUMPH-3's heart-event results are inconclusive.
• Watch for: The full TRIUMPH-3 results in a medical journal.
• First quarter of 2027: Lilly's planned FDA submission (Lilly, July 23, 2026).
• After that: FDA review. No decision date has been announced.
• Around February 2029: TRIUMPH-Outcomes' estimated end; the actual timing of results is not promised.

Will a first approval say retatrutide protects the heart? No first FDA label exists yet. A heart-protection claim would depend on the evidence FDA reviews. Wegovy's heart indication was added on March 8, 2024, after its heart trial. For where things stand on access today, see how to get retatrutide.

Questions to Ask Your Doctor (Printable Checklist)

Bring this list to your next visit. It covers what matters most for your heart before starting any GLP-1, plus what to ask if you're hoping to try retatrutide later.